MedPath

Clinical Trial News

Scemblix Demonstrates Superior Efficacy Over TKIs in First-Line CML Treatment: 96-Week ASC4FIRST Trial Results

  • Scemblix (asciminib) shows significantly higher major molecular response (MMR) rate compared to investigator-selected tyrosine kinase inhibitors (TKIs) at 96 weeks in newly diagnosed chronic myeloid leukemia (CML) patients.
  • The ASC4FIRST trial demonstrates a favorable safety profile for Scemblix, with fewer discontinuations due to adverse events compared to TKIs.
  • These findings support Scemblix as a potential first-line treatment option for CML, offering improved efficacy and tolerability.
  • The 96-week data reinforce the potential of Scemblix to change the treatment paradigm for CML patients requiring first-line therapy.

CAR-T Therapy Shows Promise in Autoimmune Diseases with Minimal Toxicities

• A phase 1/2 study of CD19 CAR-T therapy in autoimmune diseases, including lupus, myositis, and systemic sclerosis, demonstrates significant clinical responses. • The CASTLE study reports minimal toxicities, with low-grade cytokine release syndrome and no major hematotoxicities or neurotoxicity observed in patients. • Cabaletta Bio's CABA-201 shows potential for immunosuppressant-free clinical responses in refractory autoimmune diseases, with ongoing trials and planned FDA meetings. • Next-generation manufacturing processes for CAR-T therapies, like that used for CC-97540, offer faster production times and require fewer cells for infusion.

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

NCT06121297RecruitingPhase 1
Cabaletta Bio
Posted 2/16/2024

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

NCT04422912RecruitingPhase 1
Cabaletta Bio
Posted 9/29/2020

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT06328777RecruitingPhase 1
Cabaletta Bio
Posted 7/2/2024

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

NCT06154252RecruitingPhase 1
Cabaletta Bio
Posted 12/20/2023

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

NCT06359041RecruitingPhase 1
Cabaletta Bio
Posted 12/17/2024

Clearside Biomedical Highlights Suprachoroidal Delivery Tech at Global Medical Meetings

  • Clearside Biomedical showcased its suprachoroidal delivery technology and pipeline programs at medical meetings across Asia, Europe, and the United States.
  • The company's SCS Microinjector has been used in over 10,000 injections, establishing Clearside as a leader in suprachoroidal space drug delivery.
  • Presentations included ODYSSEY topline results, XIPERE real-world data, and posters on their suprachoroidal delivery platform at APVRS Congress.
  • Clearside's CLS-AX program for wet AMD is Phase 3 ready, with additional Phase 2b ODYSSEY trial data to be presented at upcoming meetings.

LifeSignals' UbiqVue 2A System Receives FDA Clearance for Continuous Wireless Patient Monitoring

  • LifeSignals' UbiqVue 2A system, featuring a wearable biosensor, has gained FDA 510(k) clearance for continuous remote patient monitoring in diverse settings.
  • The biosensor, worn on the chest, monitors 13 physiological parameters, including SpO2, ECG, respiration rate, and body temperature, transmitting data securely to a cloud-based system.
  • The UbiqVue system aims to replace manual spot-checking with continuous, near real-time monitoring, enhancing patient safety and streamlining healthcare professional workflows.
  • LifeSignals plans to expand the UbiqVue system with additional vital signs monitoring and AI capabilities through partnerships with OEMs and service providers.

FDA Approves StemCyte's REGENECYTE, a Cord Blood Stem Cell Therapy

  • The FDA has approved StemCyte's REGENECYTE, a hematopoietic progenitor cell therapy derived from umbilical cord blood, for certain hematopoietic system disorders.
  • REGENECYTE is indicated for unrelated donor hematopoietic progenitor cell transplantation in patients with inherited, acquired, or myeloablative treatment-related disorders.
  • Clinical trials demonstrated neutrophil recovery in 76-91% of patients by day 42 and platelet recovery in 45-72% of patients by day 100 post-treatment.
  • StemCyte aims to expand its cell therapy portfolio, exploring REGENECYTE's potential in aging-related diseases, chronic fatigue syndrome, and acute stroke.

HanAll, Daewoong, and NurrOn Announce Positive Phase 1 Results for Parkinson's Disease Therapy HL192 (ATH-399A)

  • HanAll Biopharma, Daewoong Pharmaceutical, and NurrOn Pharmaceuticals completed a Phase 1 study of HL192 (ATH-399A) for Parkinson's disease, meeting primary endpoints for safety and tolerability.
  • The Phase 1 trial included single ascending dose (SAD), multiple ascending dose (MAD), and food effect components in 76 healthy participants, including older adults.
  • HL192 (ATH-399A) demonstrated a favorable safety profile with no serious treatment-related adverse events and supported once-daily dosing, paving the way for further clinical trials.
  • The companies plan to initiate the next clinical trial in people with Parkinson's disease to further evaluate the safety and efficacy of HL192 (ATH-399A).

FDA Accepts Alnylam's Vutrisiran Application for ATTR Amyloidosis with Cardiomyopathy

• The FDA has accepted Alnylam's sNDA for vutrisiran to treat ATTR amyloidosis with cardiomyopathy, setting a PDUFA date of March 23, 2025. • The application is based on Phase 3 HELIOS-B trial results, which demonstrated favorable cardiovascular outcomes and improved survival in ATTR-CM patients. • If approved, vutrisiran would be the first treatment for both polyneuropathy and cardiomyopathy manifestations of ATTR amyloidosis in the U.S. • Vutrisiran's sNDA acceptance signifies a major advancement for Alnylam, potentially expanding the drug's market and solidifying its position in the ATTR space.

Capivasertib Plus Abiraterone Extends Radiographic Progression-Free Survival in PTEN-Deficient mHSPC

  • Capivasertib combined with abiraterone and ADT significantly improved radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC).
  • The CAPItello-281 Phase III trial demonstrated an early trend toward overall survival improvement, though data were immature at the time of analysis.
  • The safety profile of the capivasertib combination was consistent with the known profiles of each agent, according to AstraZeneca.
  • This combination marks the first AKT inhibitor to show benefit in this specific prostate cancer subtype, addressing a critical unmet need.

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Active, Not RecruitingPhase 3
AstraZeneca
Posted 3/25/2022

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853Active, Not RecruitingPhase 3
AstraZeneca
Posted 7/13/2020

FDA Accepts Alnylam's Vutrisiran sNDA for ATTR Amyloidosis with Cardiomyopathy

• The FDA has accepted Alnylam's sNDA for vutrisiran to treat ATTR amyloidosis with cardiomyopathy, granting priority review with a PDUFA date of March 23, 2025. • Vutrisiran, an RNAi therapeutic, targets transthyretin (TTR) and has shown favorable outcomes in the HELIOS-B Phase 3 trial for ATTR-CM patients. • The HELIOS-B study demonstrated that vutrisiran improved cardiovascular outcomes, survival, disease progression, and quality of life compared to placebo. • If approved, vutrisiran would be the first therapy in the U.S. for both polyneuropathy and cardiomyopathy manifestations of ATTR amyloidosis.

FDA Approves Imkeldi (Imatinib) Oral Solution for Certain Leukemias and Cancers

  • The FDA has approved Imkeldi (imatinib) oral solution, the first liquid formulation of imatinib, for treating certain forms of leukemia and other cancers.
  • Imkeldi is indicated for chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and gastrointestinal stromal tumors (GIST) in adults and children.
  • The oral solution offers precise dosing, a palatable strawberry flavor, and does not require refrigeration, improving adherence and accessibility for patients.
  • This approval marks Shorla Oncology's fourth FDA approval, advancing its mission to improve existing oncology treatments through formulation re-innovation.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.